Industry

Specialty and Rare Disease Few patients, few experts, no room for a missed signal

Specialty and rare disease brands are built on relationships with a small number of experts, a literature that is thin but consequential, and access decisions that can decide the brand's year. The teams are small and the stakes are high. A missed publication, a competitor's orphan designation or a change in a specialty pharmacy's criteria matters far more here than in a crowded primary care market. Blue Helix keeps that whole picture current in one place, so a small team can give each expert, each payer and each competitor the attention they deserve.

What gets in the way

Every expert matters

When a handful of clinicians shape treatment for an entire condition, each conversation counts. The MSL needs to know what that expert has published and presented, and what has changed since they last spoke, every time.

Access decisions make or break the brand

A single payer policy or a specialty pharmacy criteria change can affect a meaningful share of the patients on therapy. The team has to see those changes as they happen, not in the next quarterly review.

A small literature you cannot afford to miss

There may be only a few dozen relevant publications a year. Each one is important, and each one is easy to miss when nobody is watching systematically.

Patient finding and the funnel

Where patients are diagnosed, who treats them and where they drop out of the funnel is the whole growth story, and it is spread across epidemiology, claims patterns and clinical practice.

How the platform helps

Each product covers one part of the picture. Together they give the whole organization the same view.

Medical Affairs and Clinical Intelligence

MedIntel

Expert profiles and pre-call briefs for the clinicians who matter, a watch on the small but critical literature, and safety screening that suits a product with a narrow patient population.

Explore MedIntel Commercial and Brand Intelligence

Pharma Landscape 360

Payer and specialty pharmacy criteria, competitor and pipeline moves, the patient funnel and the catalyst calendar, in one view the brand and access teams share.

Explore Pharma Landscape 360 Data Governance and Lineage

Clarity

Patient-level and claims-derived metrics documented with their definitions and lineage, so the funnel and the forecast rest on numbers the team can defend.

Explore Clarity

Rare disease teams tend to adopt MedIntel and Pharma Landscape 360 together, because the medical and commercial pictures are so closely linked in a small market. Both are set up around your condition, your experts and your competitors.

Solutions by team

Medical affairs intelligence platform
One current view of the science, the experts and the competition for the whole medical function
MSL pre-call briefs and expert intelligence
Help field medical teams walk into every scientific exchange prepared
Literature monitoring for medical affairs and drug safety
Every relevant new publication found, screened and in front of the right team, every week
Pharma competitive intelligence platform
Competitor pipelines, readouts, approvals and deals on one calendar the whole organization can see
Market access intelligence for pharma
Formulary position, coverage criteria, pricing movements and HTA decisions, tracked together and flagged when they change
Commercial data governance for pharma
One documented definition for every table, metric and rule your commercial teams report on

Common questions

If yours isn't here, ask us directly.

Our therapy area is very narrow. Will there be enough to track?

Narrow areas benefit most. When there are few publications, few experts and few competitors, each one matters, and the value is in being certain that nothing has been missed rather than in handling volume.

Can it follow specialty pharmacy and payer criteria?

Yes. Coverage criteria, prior authorization requirements and pricing movements are tracked and flagged when they change, so the access team hears about a change while there is still time to respond.

How does it handle expert relationships?

Each expert has a profile that stays current, with what they have published and presented and what has changed since the last conversation. A brief is ready before every meeting, and what is learned afterwards is recorded where the rest of the team can see it.

We are a small team across medical and commercial. Do we need two products?

Many rare disease teams use both, because the medical and commercial pictures overlap so much in a small market. Each stands on its own, and starting with one is common.

Does it work outside the United States?

Yes. Products, competitors and geographies are set up to match your markets, and health technology assessment decisions and international access developments are followed alongside domestic ones.

Book a demo See the platform